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Abstract The multi-target screening method described in
this work allows the simultaneous detection and identifica-
tion of 700 drugs and metabolites in biological fluids using
a hybrid triple-quadrupole linear ion trap mass spectrometer
in a single analytical run. After standardization of the
method, the retention times of 700 compounds were
determined and transitions for each compound were
selected by a “scheduled” survey MRM scan, followed by
an information-dependent acquisition using the sensitive
enhanced product ion scan of a Q TRAP® hybrid instrument.
The identification of the compounds in the samples
analyzed was accomplished by searching the tandem mass
spectrometry (MS/MS) spectra against the library we
developed, which contains electrospray ionization–MS/MS
spectra of over 1,250 compounds. The multi-target screen-
ing method together with the library was included in a
software program for routine screening and quantitation to
achieve automated acquisition and library searching. With
the help of this software application, the time for evaluation
and interpretation of the results could be drastically reduced.
This new multi-target screening method has been success-
fully applied for the analysis of postmortem and traffic
offense samples as well as proficiency testing, and comple-
ments screening with immunoassays, gas chromatography–
mass spectrometry, and liquid chromatography–diode-array
detection. Other possible applications are analysis in clinical
toxicology (for intoxication cases), in psychiatry (antide-
pressants and other psychoactive drugs), and in forensic
toxicology (drugs and driving, workplace drug testing, oral
fluid analysis, drug-facilitated sexual assault).
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Introduction
Identification of drugs in biological fluids is currently
performed with a variety of analytical techniques, including
immunoassays, available only for a small number of
substance classes, and chromatographic techniques such as
gas chromatography (GC) coupled with mass spectrometry
(MS) [1] and liquid chromatography (LC) with ultraviolet
(UV) detection [2]. Although these techniques are well
established, widely used, and offer comprehensive spectral
libraries, they suffer from some limitations, including
laborious and time-consuming derivatization steps for the
analysis of nonvolatile and polar drugs by GC-MS. LC is
ideally suited for polar compounds, but UV detection does
not allow the evaluation of overlapping peaks of coeluted
compounds.
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In the last few years, LC with MS detection has been
increasingly used for toxicological screening, and different
types of instruments and strategies have been applied. High
mass resolution mass spectrometers such as time-of-flight
(TOF) instruments have been used to identify analytes by
accurate mass detection and the assignment to a molecular
formula [3] and by a further enhancement of identification
by including the isotopic pattern of the compounds [4].
Other strategies require the generation of mass-spectral
libraries to identify compounds in biological samples which
were created with single-stage mass spectrometers by “in
source” collision-induced dissociation with an inert colli-
sion gas [5, 6] or by collision-induced dissociation in a
collision cell after isolating the precursor ions to create
background-free MS/MS spectra, which were recorded
using quadrupoles [7], linear ion traps [8–11], or TOF
mass analyzers [12, 13].
Typically, LC screening methods with MS/MS identifi-
cation use a survey scan to detect analytes and a dependent
scan providing the MS/MS spectra that undergo a library
search for identification. The dependent scan can be
accomplished in a second analytical run [14] or a data-
dependent acquisition [15] or an information-dependent
acquisition (IDA) [9, 10, 12, 16–18] is used to automati-
cally select precursor ions as soon they have been detected
with the survey scan within the same analytical run. While
general unknown screening procedures can be performed
with full-scan techniques such as a Q1 scan, an enhanced
MS scan with a linear ion trap [10, 16, 17] or TOF-MS [19,
20] as the survey scan, our approach is a multi-target
screening (MTS) with a sensitive and selective multiple
reaction monitoring (MRM) for detection. For identifica-
tion, the MS/MS spectra obtained by the IDA controlled
enhanced product ion (EPI) scans are compared with the
spectra of our electrospray ionization–MS/MS library
which was previously published [8].
Compared with our former MTS [9], the method
presented here covers more target analytes, which could
be achieved with scheduled MRM (sMRM) transitions
without increasing the MRM cycle time. sMRM is used to
analyze MRM transitions only at the retention times of the
corresponding analytes within a defined time window. In
this way, fewer MRM transitions have to be monitored in
one cycle.
Furthermore, the IDA parameters were optimized to
enhance the identification of coeluted compounds: the
second most intense MRM signal of a cycle is also
considered for the dependent scan and as soon as one
MRM transition triggers a dependent scan twice in two
consecutive cycles, the corresponding precursor ion is
excluded from the dependent scan for 15 s. Although more
drugs can be detected, the total cycle time of the previous
method could be maintained by recording only one EPI
scan with a collision energy spread (CES) of 35±15 eV
instead of three spectra with collision energies of 20, 35,
and 50 eV. The acquisition of CES spectra for which the
linear ion trap is filled with product ions generated by
collision energies of 20, 35 and 50 eV prior to detection can
drastically reduce the duty cycle of an IDA screening
method, since the acquisition time for a CES spectrum is as
long as the time for one spectrum with a single collision
energy. However, the assignment of each fragmentation
pattern to a single energy level is lost.
Another analytical column and an optimized gradient
shortens the run time of the method and also its integration
together with the MS/MS library into the Cliquid® 2.0
software program, which works in conjunction with
Analyst® (both Applied Biosystems/MDS Sciex) and
enables automated acquisition, evaluation of the data
obtained, and report generation. The time reduction
achieved is over 20 min per sample.
Experimental
Reagents, standards, and samples
The internal standards (doxepin-d3 and diazepam-d5) were
purchased from Promochem/Radian (Wesel, Germany). The
system suitability test mixture containing amiodarone,
amphetamine, caffeine, codeine, diazepam, doxepin, halo-
peridol, and morphine was provided by Restek (Bad
Homburg, Germany). All solvents were of analytical grade.
High-performance LC (HPLC)-grade methanol, acetoni-
trile, and formic acid (analytical grade) were obtained from
Merck (Darmstadt, Germany). Ammonium formate (ana-
lytical grade) was from Sigma (Deisenhofen, Germany).
Deionized water was prepared with a cartridge deionizer
from Memtech (Moorenweis, Germany). Blank serum and
urine samples were obtained from the University Hospital
of Freiburg (Freiburg, Germany).
Sample preparation
For a fast and nonselective sample preparation, 100 µL of
urine was mixed with 100 µL of acetonitrile containing the
internal standards doxepin-d3 and diazepam-d5 at a
concentration of 10 µg/mL each. After vortexing and
centrifugation at 16,100×g, the supernatant was diluted
with 800 µL of water (equal to a dilution factor of 10). The
same procedure was carried out with a dilution of the
supernatant with 100 µL of water (equal to a dilution
factor of 3).
For the analysis of samples containing low concentra-
tions of analytes, an extraction procedure was carried out
before analysis: 1 mL of urine or serum sample was
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extracted by alkaline liquid–liquid extraction using 0.5 mL
of borate buffer (pH 9) followed by 1.5 mL of 1-
chlorobutane. After 4 min of mixing and 5 min of
centrifugation at 2,860×g, the organic supernatant was
transferred to an HPLC vial and evaporated to dryness
under a nitrogen stream at 40 °C. The residue was dissolved
in 100 μL of mobile phase (90:10 v/v solvent A to solvent
B). Solvent A was water with 0.2% formic acid and 2 mM
ammonium formate and solvent B was acetonitrile with
0.2% formic acid and 2 mM ammonium formate. For cases
when only a small amount of sample was available, 0.5 mL
of serum was mixed with 1 mL of borate buffer (pH 9)
prior to extraction.
Instrumentation and method
The LC-MS/MS system consisted of a 3200 Q TRAP®
triple-quadrupole linear ion trap mass spectrometer fitted
with a TurboIonSpray interface (Applied Biosystems/MDS
Sciex, Darmstadt, Germany) and a Shimadzu Prominence
HPLC system (two LC-20ADsp isocratic pumps, a CTO-
20AC column oven, an SIL-20AC autosampler, a DGU-
20A3 degasser, and a CBM-20A controller).
Separation was performed with a pentafluorophenyl
reversed-phase column (Restek Allure PFP Propyl 50 mm ×
2.1 mm inner diameter, 5 μm particle size) with an equivalent
guard column (10 mm×2.1 mm) (Restek, Bad Homburg,
Germany) and gradient elution using solvents A and B. The
gradient started with 10% of solvent B at a flow rate of
0.5 mL/min and increased within 10 min linearly to 90% at a
flow rate of 1 mL/min, which was kept for 5 min. The starting
conditions were restored within 0.5 min and kept for 2 min,
allowing the system to reequilibrate. Thirty microliters of
prepared sample was injected.
To check the LC-MS/MS system in terms of retention
times and mass-spectral performance, a system suitability
test mixture containing eight compounds (amiodarone,
amphetamine, caffeine, codeine, diazepam, doxepin, halo-
peridol, and morphine) covering the chromatographic run
time was used each day before starting the analysis of a
batch of samples.
The method consists of a survey scan and an IDA-
triggered dependent scan. As a survey scan an MRM
method with 700 transitions in positive ionization mode for
700 analytes was established by using our MS/MS library
and the MRM catalogue of Cliquid® 2.0 to automatically
select the precursor mass, the most intensive product ion,
and its corresponding collision energy. The MRM tran-
sitions were only analyzed at a time window of ±60 s and
the total cycle time of the MRM mode was 2.1 s including
the pause time between the MRM transitions of 2 ms. The
compounds with corresponding MRM transitions and
retention times are shown in Table S1.
The declustering potential was 40 V, the entrance
potential was 10 V, the cell entrance potential was mass-
dependent, the cell exit potential was 4 V, and an ion spray
voltage of 4,000 V was applied. Q1 and Q3 were used at
unit resolution (0.6–0.8 amu at half height). The gas
settings were as follows: curtain gas 20 psi; collision gas
6 psi; ion source gas 1, 40 psi; and ion source gas 2, 70 psi.
The source temperature was set to 500 °C.
The IDA intensity threshold was set to 1,000 counts per
second. The two most intense MRM transitions per cycle
exceeding this threshold were considered for the dependent
EPI scan. For further improvement of the identification of
coeluted compounds, the MRM transitions which triggered
the dependent scan twice consecutively were excluded for
EPI scans for 15 s.
The EPI scans were performed at a scan range of 50 to
700 amu after a fixed fill time of 50 ms with a scan rate of
4,000 amu/s applying a CES of 35±15 eV. Q0 trapping was
activated to accumulate ions in Q0 while concurrently
scanning ions from the linear ion trap and the pause time
after the EPI scans was set to 5 ms. The declustering
potential, entrance potential, gas values, and source
temperature were the same as used for the MRM mode.
Analyst® version 1.5 and Cliquid® 2.0 (both Applied
Biosystems/MDS Sciex) were used to operate the LC-MS/
MS system.
Results
The introduction of the scheduled MRM approach allowed
the inclusion of more target analytes in the screening
method. In sMRM mode the time the MRM transitions are
monitored in one cycle (dwell time) cannot be chosen by
the user. The total cycle time of the MRM experiment can
be defined, whereas the dwell time is calculated by the
system and depends on the number of MRM transitions that
are monitored within one cycle. To ensure that the dwell
times do not drop below 5 ms, which is supposed to be the
minimum dwell time for an MRM transition as applied for
every transition in our previous method, a closer examina-
tion of the distribution of the retention times and the
applied tolerance window is essential. For this method the
maximum overlapping retention time windows are 211 and
lie between 4 and 6 min (see Fig. 1), which is less than the
298 MRM transitions that were monitored during the
complete analytical run of our previous no scheduled
MTS. Besides the advantage of more target analytes,
sMRM also increases the sensitivity of the MRM mode,
since dwell time of more than 5 ms is available for each
transition. Furthermore, sMRM reduces the acquisition of
signals caused by matrix components which can inhibit the
acquisition of EPI spectra of coeluted analytes despite
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exclusion parameters in the IDA settings. If the matrix
component is not eluted within the retention time window
of the analyte with which it is interfering, it will not be
recorded.
A mixture of eight compounds was established to be
used as a system suitability test. The retention times of the
compounds as well as the mass spectra quality of caffeine
and diazepam were verified by Cliquid® 2.0. A chromato-
gram of the system suitability test is shown in Fig. 2.
The sensitivity of the method was tested by spiking a
serum sample with a mixture of benzodiazepines and
zolpidem (mixture 1) and a urine sample with a selection
of drugs of abuse and others (mixture 2). A liquid–liquid
Fig. 1 Distribution of the reten-
tion times of the 700 analytes
covered by the multi-target
screening. The retention time
window for every multiple re-
action monitoring (MRM)
transition is indicated by the
black bars. The maximum
overlapping retention time
windows occur between 4
and 6 min
Time. min
















Fig. 2 MRM signals of the system suitability test. The signals for
caffeine, morphine, and amiodarone have been zoomed by a factor of
5. 1 caffeine, 2 morphine, 3 codeine, 4 amphetamine, 5 diazepam, 6
doxepin, 7 haloperidol, 8 amiodarone
Table 1 Results of the analysis of a blank serum spiked with a
mixture of benzodiazepines after liquid–liquid extraction with chlor-
obutane at pH 9. For flunitrazepam and 7-aminoflunitrazepam, lower
concentrations were analyzed. The numbers are the purity values
obtained after a library search of the enhanced product ion (EPI)
spectra
Compound Concentration (ng/mL)
0 10 50 100
Bromazepam *** *** 77 82
Chlordiazepoxide *** ** 86 85
Clonazepam *** 94 **a 88
Diazepam *** 77 69 65
Flurazepam *** 85 94 91
Lorazepam *** 63 86 82
Midazolam *** 89 87 87
Nitrazepam *** * 84 89
Nordiazepam *** 64 81 77
Oxazepam *** * 71 60
Temazepam *** 82 88 76
Zolpidem *** 97 96 89
0 1 5 10
7-Aminoflunitrazepam *** 66 82 76
Flunitrazepam *** ** 86 91
*EPI quality not sufficient for identification, ** multiple reaction
monitoring (MRM) signal is positive but no acquisition of an EPI
spectrum was triggered, *** no MRM signal was detected
a The MRM signal of clonazepam was completely overlaid with the
signals of nordiazepam and temazepam and no acquisition of an EPI
spectrum was triggered. At 10 ng/mL, clonazepam is only partly
overlaid by nordiazepam. Although both are completely covered by
temazepam, the information-dependent acquisition settings allow the
identification of the three compounds, since all trigger the acquisition
of an EPI spectrum.
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extraction with chlorobutane at pH 9 was performed.
According to the “Workgroup Extraction” of the GTFCh
(Society of Toxicological and Forensic Chemistry, Ger-
many) [21], the extraction yields of the spiked compounds
are 60% for methamphetamine, 70% for MDA and
MDMA, and above 80% for the other compounds (the
extraction yields of the metabolites 7-aminoflunitrazepam,
acetylmorphine, and norfentanyl are not included).
The samples were analyzed using Cliquid® 2.0. Its
automated data processing compared the acquired EPI
spectra with our implemented library and generated a
report indicating the compounds that could be identified
and the purity values after library search. In addition to the
system suitability test prior to sample acquisition, the use of
two internal deuterated standards allowed the control of the
Compound Concentration (ng/mL)
10 10 100 100
Extraction 1 Extraction 2 Extraction 1 Extraction 2
Carbamazepine 87 86 81 70
Diphenhydramine ** ** 90 88
Phencyclidine 98 91 89 86
Norfentanyl * 74 89 94
Venlafaxine 61 87 80 84
Tilidine 75 78 70 65
Acetylmorphine 83 76 78 82
MDA 92 69 95 94
MDMA 90 88 93 91
Methamphetamine * 80 80 80
Methadone 93 81 80 81
Cocaine 97 91 84 87
Codeine 73 73 70 64
Doxepin 78 89 92 94
Fentanyl 100 100 93 96
Imipramine 89 93 91 89
Table 2 Results of the analysis
of a blank urine spiked with a
mixture of drugs of abuse and
others after liquid–liquid extrac-
tion with chlorobutane at pH 9.
The numbers are the purity
values obtained after a library
search of the EPI spectra. Each
mixture (10 and 100 ng/mL)
was extracted twice
*EPI quality not sufficient for
identification, **MRM signal is
positive but no acquisition of an
EPI spectrum was triggered
(Diazepam): ("1 / x" weighting): y = 0,0305 x + 1,6e-008 (r = 0,9984)



















Fig. 3 Calibration curve of diazepam in serum after liquid–liquid
extraction with chlorobutane at pH 9. Diazepam-d5 was used as the
internal standard
Table 3 Results of the analysis of a blank urine spiked with a mixture
of benzodiazepines after dilution. The numbers are the purity values
obtained after a library search of the EPI spectra
Compound Concentration (ng/mL)
1,000 100 100 a
Bromazepam 68 ** 79
Chlordiazepoxide 78 ** *
Clonazepam 77 * 82
Diazepam 73 ** 73
Flunitrazepam 88 * 71
Flurazepam 91 * 79
Lorazepam * ** **
Midazolam 82 65 70
Nordiazepam 77 * *
Oxazepam 65 * *
Temazepam 85 * 84
*EPI quality not sufficient for identification, ** MRM signal is
positive but no acquisition of an EPI spectrum was triggered
a The urine sample was only diluted 1:3 (v/v) with internal standard
solution in acetonitrile and water, in contrast to the other samples,
which were diluted 1:10.
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system performance. For quality control of the library
search, the spectral purity had to exceed 70% for diazepam-
d5 and doxepin-d3. If this requirement was not fulfilled
mass spectrometer maintenance had to be performed, such
as mass calibration or source cleaning.
Purity values are expressed as a percentage and were
used to characterize the spectral similarity. While the fit
value gives information about the similarity of the signals
in the library spectrum with those in the unknown
spectrum, the reverse fit value reflects the similarity of the
signals in an unknown spectrum with those of a library
spectrum. The purity is a combination of both values
displaying the measure of the unmatched peaks between the
unknown and the reference spectra. The results are shown
in Table 1 for mixture 1 and in Table 2 for mixture 2.
The areas of the MRM signals of the benzodiazepines
were used to establish calibration curves with diazepam-d5
as an internal standard to investigate the potential of the
method for semiquantitative analysis. Only for diazepam
good linearity was achieved (Fig. 3), indicating that
deuterated analogues have to be used for quantitative
purpose. This compensates signal enhancement or suppres-
sion by matrix components or coeluted analytes, to which
electrospray is susceptible [22].
Another procedure for sample preparation is dilution of
urine. It delivers fastest results without loss of compounds
due to more or less selective extraction procedures, which
are necessary for low concentrations of analytes but are
time-consuming. A urine sample was spiked with a mixture
of the benzodiazepines with 1 µg/mL and 100 ng/mL of
each compound. For the lower concentration, the urine was
not only diluted 1:10 (v/v) with internal standard solution in
methanol but also 1:3 (v/v), which could increase the
number of detected and identified compounds. The results
are summarized in Table 3.
The same procedure was performed with a mixture of
drugs of abuse and other drugs (see Table 4).
The reproducibility of the method in terms of purity
values was determined by analyzing a urine sample spiked
with a mixture of eight compounds with 1 µg/mL and
100 ng/mL of each compound. Therefore, the urine was
diluted 1:10 (v/v) and each sample was injected five times
consecutively. The minimum purities, maximum purities,
mean purities, and standard deviations are shown in
Table 5.
As expected, the sample extractions allowed the detec-
tion of lower concentrations owing to a preconcentration of
the analytes. However, it has to be taken into consideration
that no extraction method is capable of extracting all
analytes of the target screening.
Table 4 Results of the analysis of a blank urine spiked with a mixture
of drugs of abuse and others after dilution. The numbers are the purity
values obtained after a library search of the EPI spectra
Compound Concentration (ng/mL)
1,000 100 100 a
Acetylmorphine 82 ** 77
Benzoylecgonine 84 87 86
Carbamazepine 92 * *
Cocaine 95 91 94
Codeine 80 ** *
Diphenhydramine ** ** **
Doxepin 83 * 74
Fentanyl 98 94 95
Imipramine 93 65 83
MDA 96 * *
MDMA 84 67 73
Methadone 93 74 79
Methamphetamine 80 80 *
Norfentanyl 96 * *
Phencyclidine 97 93 100
Tilidine 74 75 75
Venlafaxine 87 * 64
*EPI quality not sufficient for identification, ** MRM signal is
positive but no acquisition of an EPI spectrum was triggered
a The urine sample was only diluted 1:3 (v/v) with internal standard
solution in acetonitrile and water, in contrast to the other samples,
which were diluted 1:10.
Table 5 Results of the consecutive analysis (n=5) of a blank urine
sample spiked with a mixture of compounds after a 1:10 dilution with











Benzoylecgonine 83 90 86.4 3.05
MDMA 77 88 82.8 4.32
Diazepam 60 83 71.4 9.76
Tilidine 64 80 75.0 6.75
Midazolam 71 89 84.0 7.42
Fentanyl 95 99 97.0 1.58
Phencyclidine 84 100 91.1 5.76
Methadone 54 78 67.6 9.74
Benzoylecgonine 79 85 81.8 2.68
MDMA 82 86 84.2 1.48
Diazepam 70 77 74.2 3.03
Tilidine 73 93 82.4 7.80
Midazolam 82 93 87.4 4.83
Fentanyl 90 96 94.6 2.61
Phencyclidine 95 100 97.4 2.41
Methadone 80 88 85.4 3.13
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As this method uses ion spray ionization matrix effects,
especially suppression of the analyte signals can occur and
have to be taken into account.
The method was applied to serum and urine samples of
forensic cases and was shown to be very useful as a
complementary method to GC-MS screening, HPLC–
diode-array detection (DAD), screening and immunoassays.
An example is shown in Fig. 4. The urine sample was taken
during an autopsy of a male person with suspected
intoxication as the cause of death. The urine sample was
diluted 1:10 with internal standard solution and water and
injected into the LC-MS/MS system without further sample
preparation or a hydrolysis step. The results fitted those
obtained by immunoassay, and GC-MS screening addition-
ally detected nordiazepam. It was detected by the MTS in
MRM mode, but did not exceed the threshold of the IDA
settings. Some signals in the chromatogram could not be
identified after a library search of their corresponding EPI
spectra. They might be caused by endogenous substances or
compounds that are not included in our method.
Additionally, urine samples from other autopsies were
analyzed by MTS. All the results were compared with those
of a standardized GC-MS screening after a two-step liquid–
liquid extraction and acid hydrolysis followed by liquid–
liquid extraction and acetylation according to [1] (see
Table 6).
Furthermore, the MTS was applied for serum samples of
traffic offenses and a serum sample obtained during an
autopsy after liquid–liquid extraction with chlorobutane at
pH 9. Identified compounds were quantified afterwards
with validated LC-MS/MS methods as shown in Table 7.
Finally, two interlaboratory urine proficiency tests were
performed by MTS and GC-MS screening and the results
are compared in Tables 8 and 9.
Conclusion
The improved and automatedMTS described in this paper is a
powerful tool for routine analysis of serum and urine samples
of intoxication cases for clinical and forensic purposes. Owing
to the simplicity of the sample preparation especially for urine
samples and the fast and automated processing of the data,
results can be obtained within approximately half an hour,
which is especially interesting for intoxication cases in order
to select appropriate treatments.
In cases where only low volumes of samples are
available, the dilution as a sample pretreatment offers the
possibility to perform a screening analysis with volumes as
low as 10 µL of sample.
In general, semiquantitative analysis is possible with this
method, but deuterated analogues have to be used as
internal standards to compensate matrix effects. In princi-
ple, any kind of extraction can be combined with the LC-
MS/MS screening procedure presented whenever the
extraction is adequate for the analytes of interest, and the
procedure can be applied to other matrices, such as oral
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Fig. 4 Extracted MRM chromatogram of a urine sample of a fatal
intoxication case. The urine sample was diluted with internal standard
solution and water 1:10 prior to analysis. The indicated compounds
are paracetamol (1), oxazepam (2), temazepam (3), mirtazapine (4),
diphenhydramine (5), methadone (6), and EDDP (7). In addition,
nicotine and cotinine were detected. Diazepam-d5 (I.S. 1) and
doxepin-d3 (I.S. 2) were used as internal standards
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A drawback of the method and the instrumentation is the
exclusive use of positive ionization mode, because the polarity
switching time of the mass spectrometer used would be too
long for a combination with negative ionization mode. For the
analysis of compounds that can only be ionized in negative
mode, a separate method has to be used. This problemmight be
solved in the future by improved instrumentation. The GC-MS
library of Maurer et al. used in this work, which has been
developed over more than 20 years, has the advantage of
containing many metabolites in addition to the drugs. The
inclusion of metabolites in an MTS procedure and the MS/MS
library is another aim of future method development.
In general, the combination of different complementary
methods such as immunoassays, HPLC-DAD, GC-MS, and
LC-MS/MS (MTS) was shown to be a good approach for
screening of urine and serum samples in forensic and
clinical toxicology. Furthermore, the confirmation of a GC-
MS screening result by LC-MS/MS screening fulfills the
highest requirements for identification of compounds in
cases with forensic consequences.
Table 6 Comparison of multi-target screening (MTS) and gas chromatography–mass spectrometry (GC-MS) results of autopsy cases. All urine
samples were diluted 1:10 (v/v) prior to analysis by MTS. Concentrations were determined with validated liquid chromatography–tandem mass
spectrometry (LC-MS/MS) methods. In all cases caffeine and nicotine or cotinine were identified with all methods
Detected compounds MTS dilution 1:10 GC-MS UNE GC-MS UHyAC LC-MS/MS (ng/mL)
Autopsy case 1 Carbamazepine + + −
Carbamazepine M −a + +
Carbamazepine 10,11-epoxide + −a −a
Metamizole M −a + +
Metoprolol + − −
Autopsy case 2 Diphenhydramine + + +
Diphenhydramine M −a + −
Diazepam − − + 66.4 (nordiazepam 68.2)
Oxazepam + − + 171.2
Temazepam + − − 22.7
Methadone + + +
EDDP + − −
Mirtazapine + − +
Mirtazapine M −a − +
Paracetamol + + +
Paracetamol M −a − +
Autopsy case 3 Methadone + + +
EDDP + − −
Promethazine + − +
Promethazine M −a − +
Doxepin M −a + −
Diazepam − + − 6.5
Oxazepam − − +
Heroin − − +b
Morphine 3-β-D-glucuronide + − −
Paracetamol − − +
Autopsy case 4 Doxepin + + − 10,700
Doxepin M −a + +
Methadone + + +
EDDP + + +
Oxazepam + − + 392.4
UNE standard extraction for urine, UHyAc extraction with acid hydrolysis and acetylation according to Maurer et al. [1], M metabolite(s), EDDP
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, + compound was identified, −compound could not be identified
a Compound is not included in the method
b Heroin was formed owing to the diacetylation of morphine.
6 Comparison of multi-target screening (MTS) and gas
chromatography–mass spectromet y (GC-MS) re ults of autopsy cases.
All urine samples were dilut d 1:10 (v/v) prior to analysis by MTS.
Concentr tions were determined with validated liquid chromatography–
tandem mass spectrometry (LC-MS/MS) methods. In all c ses caffeine
and nicotine or co nine ere identified with all methods
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Compound Concentration (ng/mL) MTS dilution 1:10 GC-MS UNE GC-MS UHyAc
Amphetamine 100 − − −
Midazolam 350 + + +
Benzoylecgonine 900 + − −
Pentobarbital 1,200 −a + +
EDDP 750 + − +
Phencyclidine 400 + + +
Fentanyl 100 + − +
Fluoxetine 500 + + −
Table 8 MTS and GC-MS
results of the analysis of an
interlaboratory urine proficiency
test. The spiked concentrations
are shown in the second column.
For MTS analysis the urine
sample was diluted 1:10 (v/v)
+compound was identified,
−compound could not be
identified
a Compound is not included in
the method
Table 9 MTS and GC-MS results of the analysis of an interlaboratory urine proficiency test. The spiked concentrations are shown in the second
column. For MTS analysis the urine sample was diluted 1:10 (v/v) and additionally extracted with chlorobutane at pH 9
Compound Concentration (ng/mL) MTS dilution 1:10 MTS extraction 10:1 GC-MS UNE GC-MS UHyAc
Codeine 6-glucuronide 150 −a −a − −b
MDMA 500 + + − +
Methylphenidate 800 + + + −
Nortilidine 600 −a −a + +
Nortriptyline 1,000 + + − +
Zolpidem 600 + + + +
LSD 30 − + − −
+compound was identified, −compound could not be identified
a Compound is not included in the method









Case 2 (traffic offense; serum) Nordiazepam 163.7
Diazepam 85.6
Quetiapine 157
Case 3 (traffic offense; serum) Oxazepam 33.6
Temazepam 847.5
Zolpidem 321





Case 5 (autopsy; femoral blood) Tramadol 1,411
Verapamil 416.4
Table 7 Results of the analysis
of serum/blood samples after
liquid–liquid extraction with
chlorobutane at pH 9. In each
case 0.5 mL of serum/blood was
extracted and reconstituted in
0.1 mL of solvent prior to
analysis by MTS. The concen-
trations of the identified com-
pounds were determined with
validated LC-MS/MS methods
NQ not quantified
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